Your email has been successfully added to our mailing list.

×
0 0.00206185567010312 -0.000618556701030951 -0.00247422680412366 -0.000824742268041219 -0.010721649484536 -0.00824742268041234 -0.0169072164948454
Stock impact report

Veracyte in-licenses pulmonary fibrosis test; shares ahead 4% [Seeking Alpha]

Veracyte, Inc. (VCYT) 
Last veracyte, inc. earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.veracyte.com/investor-relations
Company Research Source: Seeking Alpha
Veracyte (VCYT+3.8%agreementDr. Naftali Kaminski, chief of the Section of Pulmonary, Critical Care and Sleep Medicine in the Department of Medicine at Yale University’s School of Medicine developed the test with collaborators.The company plans to offer the non-invasive blood test as a complement to its Envisia Genomic Classifier as a comprehensive aid in the diagnosis and treatment of IPF.Financial terms are not disclosed. Show less Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
VCYT alerts

from News Quantified
Opt-in for
VCYT alerts

from News Quantified